Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
CONCLUSION: Although tumor burden has been considered a mediator of efficacy of earlier immunotherapies, in advanced lung cancer it does not appear to affect outcomes from immune checkpoint inhibitors.
IMPLICATIONS FOR PRACTICE: Historically, tumor burden has been considered an impediment to the efficacy of various immunotherapies, including vaccines, cytokines, allogeneic stem cell transplant, and intravesical bacillus Calmette-Guérin. However, in the present study, no association was found between tumor burden and efficacy (response rate, progression-free survival, overall survival) of immune checkpoint inhibitors in advanced lung cancer. These findings suggest that immune checkpoint inhibitors may provide benefit across a range of disease burden, including bulky tumors considered resistant to other categories of immunotherapy.
PMID: 32233048 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Popat V, Lu R, Ahmed M, Park JY, Xie Y, Gerber DE Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cytokine Therapy | Immunotherapy | Lung Cancer | Lung Transplant | Radiography | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Vaccines